Choosing where to receive peptide therapy is not a decision to take lightly
Alternative medication classes should be considered if GLP-1 therapy proves intolerable: SGLT2 inhibitors (such as dapagliflozin, empagliflozin) for type 2 diabetes, which work via a completely different mechanism and rarely cause gastrointestinal side effects DPP-4 inhibitors (such as sitagliptin, linagliptin), which enhance endogenous GLP-1 activity more gently Metformin remains first-line for type 2 diabetes, though it can also cause gastrointestinal side effects Orlistat for weight management, though this also has gastrointestinal side effects of a different nature For weight management specifically, NICE recommends a comprehensive approach including dietary modification, increased physical activity, and behavioural interventions, with or without pharmacotherapy
Disrupted sleep patterns are linked to increased risk of several chronic diseases
The paw withdrawal latency (PWL) to heat was measured after either intraperitoneal or oral gavage administration of glucose (2.0 g/kg body weight) in a volume of 200 L or the same volume of vehicle (0.9% saline) ( n = 5 per group)
Body composition substudy analyses using DXA scanning reveal the proportion of lean mass loss to total weight loss with Retatrutide treatment remains similar to other obesity pharmacotherapies, providing reassurance that enhanced weight loss does not translate to disproportionate muscle loss
For those considering private treatment, it is essential to use a regulated UK prescriber either a GMC-registered doctor or an NMC-registered prescribing nurse and to obtain medicines only from a GPhC-registered pharmacy or CQC-regulated provider